Document is current
Any future updates will be listed below
-
Authors
Tan, Tingyi
Vincent, Matthew
Jain, Umang
Deepak, Parakkal
,
Shukla, Richa
Dassopoulos, Themistocles
Korzenik, Josh
Snapper, Scott
Kudara, Satya
Raffals, Laura
Kaur, Manreet
Beniwal-Patel, Poonam
Cross, Ray
Hudesman, David
Ally, Mazer
Konijeti, Gauree
Matro, Rebecca
Russ, Kirk
De Felice, Kara
Pekow, Joel
Dalal, Sushila
Lidofsky, Sheldon
George, Lauren
Bishu, Shrinivas
Bewtra, Meenakshi
Lewis, James D.
Duerr, Richard
Saha, Sumona
Caldera, Freddy
Scoville, Elizabeth
-
Funding
Funding for this research was provided by:
National Institutes of Health (R01DK142751)
American College of Gastroenterology
Crohn's and Colitis Foundation of America
- License Information
-
More Information
Article History
Received: 24 November 2025
Accepted: 17 February 2026
First Online: 9 March 2026
Declarations
:
: P.D. has received research support under a sponsored research agreement unrelated to the data in the paper and/or consulting from AbbVie, Arena Pharmaceuticals, Boehringer Ingelheim, Bristol Myers Squibb, Janssen, Pfizer, Prometheus Biosciences, Takeda Pharmaceuticals, Roche Genentech, Scipher Medicine, Fresenius Kabi, Teva Pharmaceuticals, Landos Pharmaceuticals, Iterative scopes and CorEvitas, LLC. U.J. has received research support unrelated to this manuscript from Boehringer Ingelheim.
: The study protocol was approved by the Institutional Review Board (IRB) at the University of Pennsylvania which is the single IRB for the SPARC IBD study.
